Reflections About Evidence-Based Pathology
Jose Costa, MD expert. In anatomical pathology, as at the bedside, the trajectory of diagnostic inference is guided by clinical instinct, constantly reinforced by experience. The more times we have solved the problem, the better we become at solving the next one. But if we are to incorporate evidence-based practice into diagnostic anatomical pathology, the choice among alternative diagnostic methods and workup algorithms must be an informed choice, informed not by anecdote (not even repeated anecdote) but by objective evidence distilled from well-designed studies. The link between evidence and diagnostic reasoning must be transparent (so as to be easily apprehended by those in training) and continuously refined, and the evidence used to support the conclusions should be periodically updated. In the clinic, much of the objective evidence used in EBM is derived from meta-analysis of carefully designed and conducted trials.
Anatomical pathologists are in a unique position because deciphering the gross and histopathological appearance of lesions can be challenging and far from objective, although the image is considered objective relative to the clinical narrative. With some frequency, placing a lesion in a defined category involves weighing the morphological elements that compose the lesion differentially and integrating these data in the context of the information provided by other approaches (anamnesis, imaging, laboratory values, and outcomes). Choosing what morphological elements of a lesion to use in reaching a diagnosis and selecting which features will guide therapy comprise an act that can be based on experience or on EBP. Mixing the two in the right proportion is an exercise that every practicing anatomical pathologist does with a frequency dependent on the complexity of the practice environment. A vast body of scholarly work in pathology provides data on the diagnostic significance of an entire universe of morphological features for many diseases and serves as the basis for EBP. When only personal experience is used in making a diagnosis, with little reference to A significant part of a recent meeting of directors of anatomical pathology was devoted to discussing evidence-based pathology (EBP), a subject that was comprehensively treated in an issue of Seminars in Diagnostic Pathology. 1, 2 This may in part reflect a sense that anatomical pathology needs to catch up with other medical disciplines in terms of evidence-based medicine (EBM) 3 (ie, "the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients." 4(p71) ) Evidence-based medicine has emerged as a favorite teaching tool to instruct medical students and housestaff in the use of objective and rational data as the basis for deciding between alternative diagnostic, prognostic, or therapeutic choices. 5 In EBM, clinical instinct and intuition are not so much replaced as aided by the critical use of evidence (mostly derived from randomized trials), an evaluation of its strength, and patient-based inference that is carefully reasoned along the principles of logic.
The act of clinical diagnosis has traditionally rested on the capacity of the master clinician to identify, among the noise, the few cardinal elements that constitute a pattern (the disease entity) and to prove that he or she is correct judging by the efficacy of the therapy or the accuracy of the prognosis. The more noise, the more difficult it is to formulate the correct diagnostic hypothesis, and in complicated cases a final conclusion is only reached after considering several hypotheses and choosing the one most likely to be corroborated by objective data. The correct final diagnosis usually explains all the noise, and the cloud of data that may have confused the neophyte disappears under the light shed by the critically evaluated evidence, we have "pure experiential-based pathology." The more data we have regarding the value of each element of a lesion to reach a diagnosis or to guide therapy, the closer we come to EBP. The larger the number of patients used to validate the significance of a finding and the more often the study is reproduced by independent investigators, the more robust the evidence. Consensus conferences, sponsored by the College of American Pathologists, assemble multidisciplinary teams that systematically review the literature, discuss controversial areas. and select the best evidence to be used in the elaboration of guidelines for clinical use.
Yet, it is important to recognize that, no matter how strong and compelling the evidence, it needs to be adapted to the particular circumstances of the individual case. In clinical medicine, when practice is grounded in EBM, clinical judgment intervenes when translating the evidence gained from the study of cohorts of patients to an individual case. Incorporating the individuality of the illness into the general model that is the disease entity is the province of the "medical art." It is easy to see the parallel for the practice of pathology: we may use a practice algorithm to decide what panel of antibodies we shall need to workup a case, but we may interpret the results differently depending on the particular context of the case. Clearly, a good part of the diagnostic pathology literature provides databases for EBP, but there is a need for more carefully designed prospective diagnostic studies and trials. 6 Molecular medicine is shaping the diagnostic landscape by favoring trials that link the use of diagnostics to targeted therapies. Targeted therapies require the demonstration of the presence of the target and ideally an assessment of the effects of the hit. This provides a clear opportunity to conduct diagnostic trials in the context of therapeutic trials, and we can look forward to seeing this kind of study become more frequent in the coming years. Diagnostics and therapeutics will be refined in a coordinated fashion, creating databases with a dual purpose, namely, the "theragnostic" database.
As a discipline, diagnostic anatomical pathology is particularly well suited to bring EBM and EBP to the individual patient. Because its object of concern is primarily a tissue or a cell sample, the pathologist can expand the modalities used to interrogate the tissue and obtain a rich amount of objective information to realize the diagnosis. When premelanosomes are visualized in malignant tumor cells by electron microscopy, there is objective evidence for the diagnosis of melanoma. Rather than an educated guess based on the appearance of a metastatic deposit in a lymph node from a patient with no clinical history, the data in the electron micrograph speak for themselves. A regressed primary can be sought by careful examination of the somatic territory drained by the metastatic lymph node. In recent years, there has been an explosion of modalities that enable a detailed analysis of tissue, and high-density data sets can be extracted from a frozen section or from a few microdissected cells. In situ techniques, such as fluorescence in situ hybridization, can demonstrate pathognomonic translocations in tumor cells or may reveal gains and losses of genetic information. Specialized fluorescence in situ hybridization can reveal specific transcription patterns that constitute a signature for a given perturbation introduced in the system. Recent years have witnessed a dramatic increase in our capacity to probe tissues and to extract objective data. Amplifying a short segment of several cancer genes and ascertaining the presence of point mutations have become routine and constitute a powerful way to affiliate cells present in different body sites. The point here is that objective evidence can be introduced at the level of the particular case; in other words, the interpretation of the pathological findings can be corroborated by objective means, and the diagnostic inference for a particular case can be grounded on a sound basis. In this fashion, the pathologist realizes "personalized EBP." Thanks to expanded possibilities for probing the tissue (antibodies, antibody arrays, proteomics, and nucleic acid probes, to cite a few), the pathologist will be in a situation analogous to that of the prosecutor who can reopen a cold case thanks to DNA evidence linking the perpetrator to the victim with 99.9% certainty. The strength of pathology at the molecular level comes from the fact that many of the alterations demonstrated by these approaches are robust, thus resolutive of the question asked, and are causally linked to the process being studied.
The recent explosion of technologies is changing the practice of pathology and demands critical evaluation. The commercial competition for market share ensures that the creators of innovation will care to assess the effect of the technology before refining it for clinical application, but that does not relieve the end users, in this case anatomical pathologists, from designing and carrying out the studies necessary to validate technology for the diagnostic surgical pathologist. Despite computational and technological progress, many of us maintain that the need Evidence-Based Pathology / Costa 231 for medical judgment in the practice of diagnostic anatomical pathology will remain in high demand.
